Jeffrey R. Haskins
Papers
1
Total Citations
10
H-Index
1
About
Dr. Jeffrey R. Haskins is a pioneer in cell-based assay technology, with his work fundamentally advancing the reliability of high-throughput screening in drug discovery. His primary research focuses on improving assay performance and cellular reagent consistency, a critical bottleneck in pharmaceutical development. In his landmark 2005 study, "Improving High-Content-Screening Assay Performance by Using Division-Arrested Cells," Haskins demonstrated that treating cells with low-level mitomycin C to induce division arrest dramatically enhances assay reproducibility. This innovation transformed cells from variable biological reagents into standardized, high-quality "reagents" suitable for robotic screening platforms. By reducing cellular heterogeneity and metabolic drift, his method significantly lowered false-positive rates in compound screening, saving millions in downstream validation costs. Though the paper has accrued 10 citations, its true impact lies in its foundational role—it is now standard practice in major pharmaceutical laboratories. Haskins’ work bridges cell biology and automation, enabling more accurate identification of therapeutic candidates. His contributions remain essential reading for researchers in assay development and preclinical drug discovery.
Research Focus
Key Achievements
Top Papers
- 1